Premium
Prognostic factors for squamous cell cancer of the parotid gland: An analysis of 2104 patients
Author(s) -
Chen Michelle M.,
Roman Sanziana A.,
Sosa Julie A.,
Judson Benjamin L.
Publication year - 2015
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23566
Subject(s) - medicine , malignancy , parotid gland , incidence (geometry) , radiation therapy , epidemiology , oncology , cancer , disease , squamous cell cancer , head and neck , adjuvant radiotherapy , head and neck cancer , metastasis , gastroenterology , surgery , pathology , physics , optics
Background Parotid gland squamous cell cancer (SCC) occurs as metastasis from cutaneous SCC or primary malignancy. There is limited data on incidence, prognosis, and treatment outcomes. Methods The Surveillance, Epidemiology, and End Results (SEER) database (1988–2009) identified 2104 adult patients with parotid SCC. Results SCC is the second most common parotid malignancy, and its incidence is increasing (annual percentage change 1.7%; p trend = .004). Age ≥85 years, tumor size ≥4 cm, extraparenchymal extension, cervical metastases, and distant metastases were independently associated with disease‐specific mortality. Compared to no surgery, surgery was associated with improved 5‐year disease‐specific survival (DSS; 44.4% vs 71.0%; p < .001), whereas radiation alone was similar to no treatment (47.0% vs 41.6%; p = .28). Conclusion Surgery and adjuvant radiation therapy (RT) are associated with improved survival compared to radiation alone and no treatment. Patients ≥85 years of age account for nearly 20% of all patients and have a poor prognosis independent of treatment. © 2014 Wiley Periodicals, Inc. Head Neck 37 : 1–7, 2015